NAD+ for a Dog's Brain: What the Evidence Actually Shows

The first time I hear about it, it’s rarely dramatic. A family tells me their eleven-year-old Lab mix, Wallace, has started pacing at 2 a.m. instead of sleeping through the night. Or that a fourteen-year-old terrier who used to greet everyone at the door now stands in the hallway looking unsure of where she is. These are the moments that bring NAD+ into the conversation, because somewhere along the way the owner read that a supplement raises NAD+ and that low NAD+ is tied to brain aging. They want to know if that’s true, and if it means anything for the dog standing in front of them.

I think aging in dogs is better understood as information gathered over time than as a single dramatic event. No one sign tells the whole story. A slower stair climb, a missed cue, a night of restlessness — each is a data point, not a diagnosis. That framing matters here, because NAD+ decline is exactly that kind of slow, cumulative process, and it deserves a measured explanation rather than a marketing pitch.

What NAD+ actually does in the body

Nicotinamide adenine dinucleotide, or NAD+, is a coenzyme every cell needs to convert food into usable energy and to run DNA repair machinery. Levels of it decline naturally with age in mammals, dogs included, and lower cellular NAD+ has been linked to reduced mitochondrial efficiency — essentially, cells that have a harder time powering themselves and repairing damage. That’s the biological rationale behind supplementing with NAD+ precursors like nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN): raise the precursor, and in theory the cell has more raw material to rebuild its NAD+ pool.

The theory is not the same as proof of a clinical effect in a dog’s brain, and that distinction is where I get most careful with families.

The actual dog study, and what it did and didn’t find

The most directly relevant research is a randomized, controlled trial run out of North Carolina State University’s veterinary college, testing a combination of a senolytic compound and an NAD+ precursor in senior dogs and measuring owner-assessed cognition, frailty, and activity over 90 days. The results were published in Scientific Reports, and they showed measurable improvement on owner-reported cognitive and frailty scores compared with placebo. That’s a genuinely useful data point — it’s a controlled trial, not an anecdote, and it’s specific to dogs rather than extrapolated from mice or humans.

What it doesn’t show is that NAD+ alone, isolated from the senolytic component, drives the effect, or that every NAD+ precursor product behaves the same way in a dog’s body. The trial tested one specific combination at one specific protocol. It’s a floor for what’s known, not a ceiling.

Where the antioxidant ingredients fit in

Owners often ask me about the other ingredients that show up alongside NAD+ precursors in longevity chews — quercetin and resveratrol most commonly. Quercetin is a flavonoid studied for antioxidant, immune, and cellular support properties, and current research is still working out its practical relevance at supplement-level doses; one in vitro study found that quercetin formulations, along with related antioxidant compounds, did not affect feeding behavior in the model organism tested at the concentrations used, which is a narrow but real finding worth knowing rather than ignoring (Pharmaceuticals). Resveratrol has a more complicated dosing picture — one in vitro study found that embryonic exposure to a specific resveratrol concentration accelerated developmental timing but shortened adult lifespan in the model organism, a reminder that “antioxidant” doesn’t automatically mean “more is better” (Phytomedicine).

I bring these two into the same conversation as NAD+ precursors because families sometimes treat a longevity chew as a single ingredient when it’s usually a blend, and each component in that blend has its own separate evidence base, strength, and limits.

A case that stuck with me

I once worked with a nine-year-old Cavalier King Charles Spaniel named Biscuit, about 19 pounds, whose owner first noticed a change on a Tuesday morning in early winter: Biscuit hesitated at the bottom of the porch steps for a full three seconds before going up, something she’d never done. Over the following six weeks, the owner logged a slower rise from the couch after naps and two nights of unusual wandering in the kitchen around 3 a.m. She’d read about NAD+ supplements online and asked whether to start one immediately or wait for our senior wellness exam, which was five weeks out. We talked through the tradeoff — cost, whether Biscuit would even eat a chew given her picky history, and what we’d actually be measuring for. We moved her exam up instead of guessing. That decision, not the supplement question itself, was the one that mattered most in the moment.

Recognizing the signs worth bringing to your vet

Cognitive changes in senior dogs tend to cluster around a recognizable set of behaviors, sometimes summarized by veterinary reviewers using the acronym DISHAAL — disorientation, altered interactions with familiar people, sleep-wake disturbances, house soiling, activity changes, anxiety, and learning or memory changes, as described in a Diagnosis of Canine Cognitive Dysfunction Syndrome: A Narrative Review: narrative review of canine cognitive dysfunction syndrome diagnosis. None of these signs alone is diagnostic. What matters is the pattern and the pace of change, which is exactly why I ask families to describe timelines rather than single incidents.

Front-leg gait changes are one of the more overlooked markers families miss because they read as a mobility issue rather than a cognitive one; our related piece on what shorter front-leg steps may tell us about cognitive change in senior dogs walks through why that particular sign deserves a second look.

How I actually approach the conversation

In my practice, I don’t dismiss NAD+ precursors as unproven fads, and I also don’t present them as established treatment. I tell families what the North Carolina State trial found, I tell them what it didn’t isolate, and I ask them to bring their observations — not a purchase decision — to the exam room first. The American Animal Hospital Association: AAHA Senior Care Guidelines emphasize exactly this: cognitive dysfunction management works best when it’s paired with a full veterinary workup that rules out medical causes of the same symptoms, since pain, thyroid disease, and sensory loss can all mimic cognitive decline. A supplement, however well-studied, isn’t a substitute for that workup.

I’ve also watched owners start a supplement on their own before that exam, hopeful it might undo confusion that had built over months. Research on how frequently families reach for these products before or alongside a diagnosis, described in a study investigating owner use of dietary supplements in dogs with canine cognitive dysfunction, suggests this pattern is common rather than rare. It’s understandable — a slipping dog creates urgency — but the sequence matters. Diagnosis first, then a grounded decision about what, if anything, to add.

The bottom line

NAD+ decline is real biology, and one controlled trial in senior dogs found a measurable benefit from a specific NAD+ precursor and senolytic combination on owner-reported cognition and frailty — that’s more than most longevity ingredients can claim, and it’s worth taking seriously. But it’s a single trial testing a specific combination, not a blanket endorsement of every NAD+ product on a shelf, and it doesn’t replace a veterinary exam that rules out the medical conditions that mimic cognitive decline in the first place. If your dog is showing a new pattern of disorientation, altered sleep, or house soiling, start with that exam, bring your specific observations with dates and details, and treat any supplement conversation as the second step, not the first.